Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Healthy Volunteer Study of the Pharmacokinetics of Oral Piperaquine With OZ439 + TPGS Formulation in the Fasted State

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01853475
Recruitment Status : Completed
First Posted : May 15, 2013
Results First Posted : April 8, 2015
Last Update Posted : April 30, 2015
Sponsor:
Collaborator:
Richmond Pharmacology Limited
Information provided by (Responsible Party):
Medicines for Malaria Venture

Brief Summary:

Piperaquine tablets (coated) + OZ439 granules + TPGS granules will be co-administered in Phase IIb (adults). However, safety and PK data (for OZ439 plus piperaquine) were obtained using piperaquine tablets plus OZ439 as Powder in Bottle with milk. Piperaquine has not yet been administered together with TPGS. Co-administration of piperaquine plus OZ439 as Powder in Bottle (PIB) with milk results in an increase in OZ439 exposure (current estimate ~ 70% due to a small drug drug interaction).

This study investigates the exposure of piperaquine and OZ439 when co-administered as piperaquine phosphate tablets and OZ439 + TPGS prototype (a formulation close to that of Phase IIb, but not identical), in order to select the appropriate doses for Phase IIb. The reference treatment is piperaquine phosphate tablets + OZ439 Powder in Bottle + full fat milk


Condition or disease Intervention/treatment Phase
Malaria Drug: PQP tablets 960mg Drug: PQP tablets 1440mg Drug: OZ439+TPGS 800mg Drug: OZ439 PIB 800mg Phase 1

Detailed Description:

Objectives:

  1. To evaluate the piperaquine and OZ439 pharmacokinetics when administered as a combination of piperaquine phosphate tablets with OZ439 / TPGS formulation in the fasted state
  2. To evaluate the piperaquine and OZ439 pharmacokinetics of a reference free combination formulation: piperaquine phosphate tablets with OZ439 powder in bottle (PIB) given with full fat milk
  3. To determine safety and tolerability of OZ439 and piperaquine phosphate when co-administered.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open Label, Parallel Group Study to Investigate the Pharmacokinetics (PK) Following Oral Co-administration of Piperaquine Phosphate (PQP) Tablets With a Prototype OZ439 + TPGS Formulation in the Fasted State in Healthy Volunteers
Study Start Date : April 2013
Actual Primary Completion Date : July 2013
Actual Study Completion Date : July 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Malaria

Arm Intervention/treatment
Experimental: Treatment A
PQP tablets 1440mg and OZ439+TPGS 800mg co-administered as a single oral dose fasted.
Drug: PQP tablets 1440mg
Piperaquine phosphate tablets 1440mg

Drug: OZ439+TPGS 800mg
OZ439+TPGS prototype formulation 800mg

Experimental: Treatment B
PQP tablets 960mg and OZ439+TPGS 800mg co-administered as a single oral dose fasted.
Drug: PQP tablets 960mg
Piperaquine phosphate tablets 960mg

Drug: OZ439+TPGS 800mg
OZ439+TPGS prototype formulation 800mg

Active Comparator: Treatment C - Reference
PQP Tablets 1440 mg and OZ439 PIB 800mg + full fat cow's milk
Drug: PQP tablets 1440mg
Piperaquine phosphate tablets 1440mg

Drug: OZ439 PIB 800mg
OZ439 Powder in Bottle Aqueous Solution 800mg




Primary Outcome Measures :
  1. OZ439 Cmax [ Time Frame: Day 1 pre-dose and post-dose at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16 and 24 hours(Day 2), and, 48 (Day 3), 72 (Day 4), 96 (Day 5),168 (Day 8), Day 11, Day 15, Day 29 and Day 43 ]
    OZ439 maximum concentration observed

  2. OZ439 AUC0-inf [ Time Frame: Day 1 pre-dose and post-dose at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16 and 24 hours(Day 2), and, 48 (Day 3), 72 (Day 4), 96 (Day 5),168 (Day 8), Day 11, Day 15, Day 29 and Day 43 ]
    Area under the OZ439 plasma concentration time curve from time zero to time infinity using observed values.


Secondary Outcome Measures :
  1. Piperaquine Cmax [ Time Frame: Day 1 pre-dose and post-dose at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16 and 24 hours(Day 2), and, 48 (Day 3), 72 (Day 4), 96 (Day 5),168 (Day 8), Day 11, Day 15, Day 29 and Day 43 ]
    Piperaquine maximum concentration observed

  2. Piperaquine AUC0-inf [ Time Frame: Day 1 pre-dose and post-dose at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16 and 24 hours(Day 2), and, 48 (Day 3), 72 (Day 4), 96 (Day 5),168 (Day 8), Day 11, Day 15, Day 29 and Day 43 ]
    Area under the Piperaquine plasma concentration time curve from time zero to time infinity using observed values.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Healthy male/female of any race aged 18-55 years at screening
  2. Body Mass Index 18-30kg/m2; body weight >50kg but no more than 100kg at screening
  3. Females with negative pregnancy test at screening and admission, non-lactating and of non-child bearing potential confirmed
  4. Agree to use acceptable methods of contraception
  5. Should not donate egg and sperm from the time of administration of treatment or study medication until 3 months following dose of study medication
  6. Must be capable of understanding and complying with the requirements of the protocol and must have signed the informed consent form prior to undergoing any study-related procedures

Exclusion Criteria:

  1. Male subjects with a female partner(s) who is (are) pregnant or lactating from the time of the administration of study medication
  2. Has a clinically significant disease or any condition or disease that might affect drug absorption, distribution or excretion, e.g. gastrectomy, diarrhoea.
  3. History of allergic reactions to artemisinin-based compounds, 4-aminoquinolines such as piperaquine or any other clinically relevant allergy to drugs or food.
  4. Any clinically relevant history of cow's milk intolerance/allergy.
  5. Any clinically significant abnormal laboratory, vital signs or other safety findings as determined by medical history, physical examination or other evaluations conducted at screening or on admission. Exception is PR, QTcB, QTcF, cardiac rhythm, liver function tests and haemoglobin that must be within the normal reference range at screening and on admission.
  6. History or current evidence of any clinically relevant cardiovascular, pulmonary, hepatic, renal, gastrointestinal (excluding appendectomy and cholecystectomy), haematological, endocrinological, immunological, metabolic, neurological, oncological, psychiatric, urological or other disease, or current infection
  7. History of post-antibiotic colitis
  8. Electrocardiogram abnormalities in the standard 12-lead (at screening) and/or 24-hour 5 lead Holter (at screening) which in the opinion of the Investigator is clinically relevant or will interfere with the analysis
  9. A history of clinically significant electrocardiogram abnormalities, or any of the following abnormalities at screening or admission:

    • PR >200 msec
    • QRS complex >120 msec
    • QTcB or QTcF >450 msec or shortened QTcB or QTcF less than 340 msec for males and females or family history of long QT syndrome or sudden death
    • Any degree of heart block (such as first, second or third degree atrioventricular block, incomplete, full or intermittent bundle branch block)
    • Abnormal T wave morphology / prominent U waves
    • Potassium levels out of the normal range at screening and prior to dosing
  10. Positive results in any of the serology tests for Hepatitis B Surface Antigen, anti Hepatitis core antibody, Hepatitis C antibodies, and Human Immunodeficiency Virus 1 and 2 antibodies
  11. Confirmed positive results from urine drug screen (amphetamines, benzodiazepines, cocaine, cannabinoids, opiates, barbiturates, and methadone) or from the alcohol breath test at screening and admission
  12. History or clinical evidence of alcohol abuse, or any recreational drug abuse within the 2 years prior to screening
  13. Mentally handicapped
  14. Participation in a drug trial within 90 days prior to drug administration
  15. Use of ANY prescription or over the counter medications, within 3 weeks of study drug administration, or vitamins or herbal supplements within 2 week of administration of the drug administration of study drug (or at least 5 half-lives of the compound whichever period is the longer), unless prior approval is granted by both the Investigator and Sponsor. Excluded from this list is intermittent use of paracetamol at up to 2g/day.
  16. Use moderate or strong inhibitors and/or inducers of cytochrome CYP450 within 4 weeks prior to the planned drug administration (or at least 5 half-lives of the compound whichever period is the longer)
  17. Subjects have veins unsuitable for intravenous puncture or cannulation on either arm (e.g. veins that are difficult to locate, access or puncture veins with a tendency to rupture during or after puncture)
  18. Blood liver function tests not in the normal range at screening and on admission
  19. Haemoglobin is less than the lower limit of the reference range at screening and on admission.
  20. Donation of more than 500mL blood within 90 days prior to drug administration
  21. Subjects must be non-smokers for at least 3 months prior to screening Note: "Tobacco use" includes smoking and the use of snuff and chewing tobacco, and other nicotine or nicotine containing products
  22. Any consumption of grapefruit, Seville oranges, wild grapes, black mulberries, pomegranates in the form of fruit juice, marmalade or as a raw fruit within 7 days prior to dosing of study drug and throughout the study. Any circumstances or conditions, which, in the opinion of the investigator may affect full participation in the trial or compliance with the protocol
  23. Legal incapacity or limited legal capacity at screening
  24. Vegetarians, vegans or any dietary restrictions conflicting with the study standardised menus

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01853475


Locations
Layout table for location information
United Kingdom
Richmond Pharmacology Limited
Croyden, London, United Kingdom, CR7 7YE
Sponsors and Collaborators
Medicines for Malaria Venture
Richmond Pharmacology Limited
Investigators
Layout table for investigator information
Principal Investigator: Ulrike Lorch, MD FRCA FFPM Richmond Pharmacology Limited
Layout table for additonal information
Responsible Party: Medicines for Malaria Venture
ClinicalTrials.gov Identifier: NCT01853475    
Other Study ID Numbers: MMV_OZ439_13_002
2013-000983-28 ( EudraCT Number )
First Posted: May 15, 2013    Key Record Dates
Results First Posted: April 8, 2015
Last Update Posted: April 30, 2015
Last Verified: April 2015
Keywords provided by Medicines for Malaria Venture:
pharmacokinetics
safety
tolerability
bioavailability
Additional relevant MeSH terms:
Layout table for MeSH terms
Malaria
Protozoan Infections
Parasitic Diseases